Management & Regulatory

Investors often seek avenues that can offer significant returns while mitigating risks. The biopharma sector, with its blend of innovation and high stakes, has captured the attention of hedge fund managers and investors alike. But can biopharma hedge funds truly be the key to outperforming the

Bain Capital Life Sciences has made headlines with the closure of its new $3 billion biotech fund, the largest in its seven-year history. This monumental step aligns with the firm's continuous efforts since its inception in 2016 to bolster the biotech sector by funding ventures that address

In a notable turn of events, Allspring Global Investments Holdings LLC has dramatically boosted its stake in Xeris Biopharma Holdings, a leading biopharmaceutical company known for its innovative therapies for patients with unmet medical needs. Documented in the latest Form 13F filing with the

In a determined effort to adhere to Nasdaq listing requirements and secure its position in a competitive market, Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, has executed a 1-for-25 reverse stock split. Effective August 19, 2024, this strategic maneuver aims to elevate the

RedHill Biopharma Ltd., known for its focus on gastrointestinal and infectious diseases, has recently achieved compliance with Nasdaq's minimum bid price requirement. This milestone ensures that the specialty biopharmaceutical company will continue to be listed on the Nasdaq Capital Market, a

In a significant move that is set to reshape the biopharmaceutical landscape, Tanvex BioPharma is acquiring Bora Biologics, a subsidiary of Bora Pharmaceuticals. This strategic merger aims to amalgamate the strengths of two industry leaders, creating a formidable force in the global Contract